Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, announced today that investigators for the Company's Phase I/II clinical trials for Stargardt's macular dystrophy and dry age-related macular degeneration have observed evidence of engraftment of the transplanted human embryonic stem cell -derived retinal pigment ... (more)
http://technews.tmcnet.com/news/2013/01/08/6836936.htm
http://technews.tmcnet.com/news/2013/01/08/6836936.htm
No comments:
Post a Comment